» Articles » PMID: 29247214

Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells

Overview
Journal Sci Rep
Specialty Science
Date 2017 Dec 17
PMID 29247214
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Cholangiocarcinoma (CCA) is a devastating liver tumour arising from malignant transformation of bile duct epithelial cells. Cancer stem cells (CSC) are a subset of tumour cells endowed with stem-like properties, which play a role in tumour initiation, recurrence and metastasis. In appropriate conditions, CSC form 3D spheres (SPH), which retain stem-like tumour-initiating features. Here, we found different expression of iron proteins indicating increased iron content, oxidative stress and higher expression of CSC markers in CCA-SPH compared to tumour cells growing as monolayers. Exposure to the iron chelator desferrioxamine decreased SPH forming efficiency and the expression of CSC markers and stem-like genes, whereas iron had an opposite effect. Microarray profiles in CCA samples (n = 104) showed decreased H ferritin, hepcidin and ferroportin expression in tumours respect to surrounding liver, whereas transferrin receptor was up-regulated. Moreover, we found a trend toward poorer outcome in CCA patients with elevated expression of ferritin and hepcidin, two major proteins of iron metabolism. These findings, which represent the first evidence of a role for iron in the stem cell compartment as a novel metabolic factor involved in CCA growth, may have implications for a better therapeutic approach.

Citing Articles

Reprogramming of fatty acid metabolism: a hidden force regulating the occurrence and progression of cholangiocarcinoma.

Zhang J, Ruan K, Chu Z, Wang X, Gu Y, Jin H Cell Death Discov. 2025; 11(1):72.

PMID: 39984452 PMC: 11845788. DOI: 10.1038/s41420-025-02351-w.


ACSL3 is an unfavorable prognostic marker in cholangiocarcinoma patients and confers ferroptosis resistance in cholangiocarcinoma cells.

Sae-Fung A, Vinayavekhin N, Fadeel B, Jitkaew S NPJ Precis Oncol. 2024; 8(1):284.

PMID: 39706856 PMC: 11662031. DOI: 10.1038/s41698-024-00783-8.


Emerging insights into ferroptosis in cholangiocarcinoma (Review).

Zhao X, Zhang M, He J, Li X, Zhuang X Oncol Lett. 2024; 28(6):606.

PMID: 39483963 PMC: 11526429. DOI: 10.3892/ol.2024.14739.


A live single-cell reporter system reveals drug-induced plasticity of a cancer stem cell-like population in cholangiocarcinoma.

Kongtanawanich K, Prasopporn S, Jamnongsong S, Thongsin N, Payungwong T, Okada S Sci Rep. 2024; 14(1):22619.

PMID: 39349745 PMC: 11442615. DOI: 10.1038/s41598-024-73581-8.


Iron metabolism: backfire of cancer cell stemness and therapeutic modalities.

Yu R, Hang Y, Tsai H, Wang D, Zhu H Cancer Cell Int. 2024; 24(1):157.

PMID: 38704599 PMC: 11070091. DOI: 10.1186/s12935-024-03329-x.


References
1.
Vaquero J, Guedj N, Claperon A, Nguyen Ho-Bouldoires T, Paradis V, Fouassier L . Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. J Hepatol. 2016; 66(2):424-441. DOI: 10.1016/j.jhep.2016.09.010. View

2.
Drakesmith H, Nemeth E, Ganz T . Ironing out Ferroportin. Cell Metab. 2015; 22(5):777-87. PMC: 4635047. DOI: 10.1016/j.cmet.2015.09.006. View

3.
Brookes M, Boult J, Roberts K, Cooper B, Hotchin N, Matthews G . A role for iron in Wnt signalling. Oncogene. 2007; 27(7):966-75. DOI: 10.1038/sj.onc.1210711. View

4.
Kakhlon O, Gruenbaum Y, Cabantchik Z . Ferritin expression modulates cell cycle dynamics and cell responsiveness to H-ras-induced growth via expansion of the labile iron pool. Biochem J. 2002; 363(Pt 3):431-6. PMC: 1222495. DOI: 10.1042/0264-6021:3630431. View

5.
Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S . Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009; 15(6):501-13. PMC: 2693960. DOI: 10.1016/j.ccr.2009.03.018. View